80 New research into the treatment of ampullary cancer (AmC) has questioned the efficacy of adjuvant therapies, particularly chemotherapy and radiotherapy, in improving overall survival rates. A comprehensive meta-analysis of 21 studies, involving 3,971 patients, shows that while adjuvant treatment is commonly administered after surgical resection, its overall impact on survival remains uncertain. The findings were published in the journal Hepatobiliary & Pancreatic Diseases International. Ampullary cancer, a rare form of cancer that occurs where the bile duct and pancreatic duct meet, is typically treated through surgical resection. The prognosis for AmC patients has historically been better than other gastrointestinal cancers, with post-surgery five-year survival rates ranging from 33–70%. But the use of adjuvant therapies after surgery has been a subject of debate. The meta-analysis aimed to assess whether adjuvant therapy, which includes chemotherapy or combined chemoradiotherapy, improves outcomes for patients. Data from the studies were pooled, comparing overall survival (OS) and recurrence-free survival (RFS) in patients who received adjuvant treatment (AT) and those who did not (nAT). Surprisingly, the analysis showed no significant difference in overall survival between the two groups. The hazard ratio (HR) for OS in patients who received adjuvant therapy was close to 1.0, indicating that the survival advantage of AT is minimal at best. The recurrence rates were also similar between the two groups, further casting doubt on the routine use of adjuvant treatment. While the overall effect of adjuvant therapy appeared limited, subgroup analysis offered a more detailed picture. Patients with lymph node involvement, a factor that usually indicates more aggressive cancer, seemed to benefit from adjuvant therapy. In these patients, AT was associated with improved survival outcomes. The HR for patients with nodal involvement was 0.627, suggesting a significant reduction in mortality risk compared to those who did not receive adjuvant therapy. But when the data was broken down further, neither chemotherapy alone nor combined chemoradiotherapy showed a substantial survival benefit for the broader AmC patient population. These findings suggest that the potential benefits of adjuvant therapy may be more selective, particularly for patients with more advanced or nodal-positive disease. The results of this meta-analysis have important implications for how ampullary cancer is treated. For patients without lymph node involvement, adjuvant therapy may offer little to no additional benefit over surgery alone. However, for those with lymph nodal involvement, the evidence supports the use of adjuvant treatment as part of a comprehensive care plan. The absence of a clear survival benefit for adjuvant therapy in the general AmC population may lead to more tailored treatment approaches. Clinicians may focus on identifying which patients are most likely to benefit from these treatments, particularly those with more aggressive forms of the disease. Additionally, further research may be needed to refine treatment strategies and explore new therapeutic approaches. Although adjuvant therapy has been a common follow-up to surgery in the treatment of ampullary cancer, its benefits are not uniform across all patients. This study underscores the complexity of treating AmC and highlights the need for more personalised approaches based on individual patient characteristics, particularly lymph node involvement.